glp-1 shortage fda The says it's standing by its earlier decision that the of tirzepatide — the active ingredient in Eli Lilly's diabetes and weight loss drugs Mounjaro and Zepbound — is over GLP-1 No Longer on FDA's
Description
While GEP-44 remains in preclinical development, these early findings position SureNano Science within a highly strategic segment of the obesity treatment landscape

Rotating injection sites each week can help reduce irritation and improve comfort

Even Lilly Direct at $499/month works out to ~$5,988/year before any interest

However, he cautions that the science is still developing

Martin, B